Angela DeMichele
Abramson Cancer Center at Penn Medicine · University of Pennsylvania · Abramson Cancer Center of University of Pennsylvania
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
4
1 more share only the name and are not shown
Trial papers
85
PubMed author-name match
Trials
Studies that name Angela DeMichele as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06551116 · QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast CancerAbramson Cancer Center at Penn Medicine · recruiting · HER2-positive Metastatic Breast Cancer · principal investigator
- Ph2NCT04841148 · Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerAbramson Cancer Center at Penn Medicine · active not recruiting · Breast Cancer · principal investigator
- Ph1/Ph2NCT03400254 · Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")Abramson Cancer Center at Penn Medicine · withdrawn · Breast Cancer · principal investigator
- Ph2NCT03032406 · CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast CancerAbramson Cancer Center at Penn Medicine · active not recruiting · Breast Cancer Stage IIB · principal investigator
- N/ANCT02830282 · Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast CancerAbramson Cancer Center at Penn Medicine · completed · Breast Cancer · principal investigator
- N/ANCT02798341 · The Breast Program - Translational Cancer ResourceAbramson Cancer Center at Penn Medicine · active not recruiting · Breast Cancer · principal investigator
- N/ANCT02732171 · PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast CancerAbramson Cancer Center at Penn Medicine · recruiting · Breast Cancer · principal investigator
- N/ANCT02530008 · Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast CancerAbramson Cancer Center at Penn Medicine · active not recruiting · Women With Suspected or Confirmed Recurrent Breast Cancer · principal investigator
- Ph3NCT02513394 · PALbociclib CoLlaborative Adjuvant StudyAlliance Foundation Trials, LLC. · active not recruiting · Breast Cancer · principal investigator
- N/ANCT01153282 · Physical Functional Side Effects of Taxane Chemotherapy for Breast CancerAbramson Cancer Center at Penn Medicine · completed · Breast Cancer · principal investigator
- Ph2NCT00472693 · Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast CancerAbramson Cancer Center at Penn Medicine · completed · Breast Cancer · principal investigator
- Ph2NCT00343759 · Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted TherapyUniversity of Pennsylvania · withdrawn · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Breast Cancer ProgramP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2016 to 2026 · $371,316 awarded in 2026Same name and institution; not confirmed by an ID
- Secondary Prevention through Surveillance and InterventionR01CA208273 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2017 to 2021 · $634,332 awarded in 2021Same name and institution; not confirmed by an ID
- Molecular & Genetic Determinants of Outcome in Breast CancerR01CA104581 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2004 to 2008 · $296,181 awarded in 2008Same name and institution; not confirmed by an ID
- AGE, CELL CYCLE MARKERS AND BREAST CANCER OUTCOMESK23CA081009 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 1999 to 2004 · $61,257 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 85 PubMed records, and a shared surname and initials can bring in a namesake. All 85 on PubMed
- 1,471 citationsRCR 45.8
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- 620 citationsRCR 24.3
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.Cancer Immunol Res · 2017398 citationsRCR 11.6
- 372 citationsRCR 10.9
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.J Clin Oncol · 2019371 citationsRCR 12.2
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.Autophagy · 2014315 citationsRCR 9.0
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.Clin Cancer Res · 2012306 citationsRCR 7.0